Skip to main content
Top
Published in: Annals of Hematology 9/2009

01-09-2009 | Letter to the Editor

Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma

Authors: Adrian Tempescul, Jean-Christophe Ianotto, Frederic Morel, Veronique Marion, Marc De Braekeleer, Christian Berthou

Published in: Annals of Hematology | Issue 9/2009

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36(2):115–127 (review)PubMed Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36(2):115–127 (review)PubMed
3.
go back to reference Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83(3):758–766PubMed Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83(3):758–766PubMed
4.
go back to reference Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, Banchereau J, Liu YJ (1996) −Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 183(1):227–236. doi:10.1084/jem.183.1.227 PubMedCrossRef Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, Banchereau J, Liu YJ (1996) −Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 183(1):227–236. doi:10.​1084/​jem.​183.​1.​227 PubMedCrossRef
5.
go back to reference Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed
6.
go back to reference Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47(7):1105–1114PubMed Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47(7):1105–1114PubMed
7.
go back to reference Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104(8):2269–2271. doi:10.1182/blood-2004-03-1091 PubMedCrossRef Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104(8):2269–2271. doi:10.​1182/​blood-2004-03-1091 PubMedCrossRef
10.
go back to reference Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B (2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140(3):313–319. doi:10.1111/j.1365-2141.2007.06937.x PubMedCrossRef Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B (2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140(3):313–319. doi:10.​1111/​j.​1365-2141.​2007.​06937.​x PubMedCrossRef
11.
go back to reference Wang M, Fayad L, Hegemeister F et al (2007) A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 25:8030 Wang M, Fayad L, Hegemeister F et al (2007) A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 25:8030
Metadata
Title
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma
Authors
Adrian Tempescul
Jean-Christophe Ianotto
Frederic Morel
Veronique Marion
Marc De Braekeleer
Christian Berthou
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0692-4

Other articles of this Issue 9/2009

Annals of Hematology 9/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.